Acute versus chronic myocardial ischemia: A differential biological profile study

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 2, 2008, Pages 91-97

  Sagastagoitia, José Domingo ^a   Sáez, Yolanda ^b   Vacas, Marta ^b   Narváez, Idoia ^b   Sáez De Lafuente, Jesús Pablo ^c   Molinero, Enrique ^a   Escobar, Antonio ^a   Lafita, Manuel ^b   Iriarte, José Antonio ^b  

^a HOSPITAL DE BASURTO   (Spain)

^b FIDEC Fundacion para la Investigacion Y Docencia de Las Enfermedades Cardiovasculares   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Acute myocardial ischaemia; Chronic myocardial ischaemia; Risk factors

Indexed keywords

APOLIPOPROTEIN A1; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE DISEASE; ADULT; AGED; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HUMAN; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LIPIDS; LIPOPROTEIN(A); MALE; MICROVASCULAR ANGINA; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; THROMBOSIS;

EID: 58549119582     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173728     Document Type: Article

References (45)

1. Oparil S, Oberman A: Non-traditional cardiovascular risk factors. Am J Med Sci 1999;317:193-207.
2. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, et al: Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994;271:999-1003.
3. Batalla Velorio A, Rodríguez Reguero JJ, Iglesias Cubero G, Hevia Nava S, Braga Fernández S, Fernández Bustillo E, et al: Lipoprotein (a) as a predictor of severity of coronary artery stenosis documented by angiography in male coronary patients under 50 years old. Rev Esp Cardiol 2000;53:1047-1051.
4. Folsom AR: Fibrinogen and cardiovascular risk markers. Blood Coagul Fibrinolysis 1999;10(supp1):S13-S16.
5. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al: Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001;103:2323-2327.
6. Hoffmeister A, Rothenbacher D, Bäzner U, Fröhlich M, Brenner H, Hombach V, et al: Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 2001;87:262-266.
7. Fuster V, Baunwald E: Unstable angina: definition, pathogenesis, and classification; in Fuster V, Ross R, Topol E (eds): Atherosclerosis and Coronary Artery Disease. Philadelphia, Lippincott-Raven, 1996, vol 2, pp 1285-1297.
8. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
9. Madjid M, Awan I, Willerson JT, Casscells W: Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004;44:1945-1956.
10. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al: C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. Circulation 2005;112:25-31.
11. Bayés-Genis, Mateo J, Santaló M, Oliver A, Guindo J, Badimon L, et al: D-dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am Heart J 2000;40:379-384.
12. Hoffmeister HM, Heller W, Seipel L: Molecular markers of hemostasis and fibrinolysis and inhibitor levels in unstable angina pectoris. Fibrinolysis Proteolysis 1997;11(suppl 1):61-65.
13. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-641.
14. Toss H, Lindahl B, Siegbahn A, Wallentin L: Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease: FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997;96:4204-4210.
15. English JP, Willius FA, Berkson J: Tobacco and coronary disease. JAMA 1940;115:1327-1329.
16. Kannel WB: Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 1976;37:269-282.
17. Ludvig J, Miner B, Eisenberg MJ: Smoking cessation in patients with coronary artery disease. Am Heart J 2005;149:565-572.
18. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q: Nicotine effects on eicosanoid formation and hemostatic function comparison of transdermal nicotine and cigarette-smoking. J Am Coll Cardiol 1993;22:1159-1167.
19. Quillen JE, Rossen JD, Oskarsson HJ, Minor RL, López AG, Winniford MD: Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. J Am Coll Cardiol 1993;22:642-647.
20. Berg K: A new serum system in man: the Lp(a) system. Acta Pathol Microbiol Scand 1963;59:369-382.
21. Utermann G, Weber W: Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett 1983;154:357-361.
22. Marcovina SM, Koschinsky ML: A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med 2002;2:335-344.
23. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF: A potential basis for the thrombotic risk associated with lipoprotein (a). Nature 1989;339:301-303.
24. Haijar KA, Gavish D, Breslow JL, Nachman RL: Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-305.
25. Von Hodenberg E, Pestel E, Kreuzer J, Freitag M, Bode C: Effects of lipoprotein (a) on thrombosis. Chem Phys Lipids 1994;67-68:381-385.
26. MBewu AD, Durrington PN, Mackness MI, Hunt L, Turkie WH, Creamer JE: Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J 1994;71:316-321.
27. Brugemann J, van der Meer J, Hillege HL, et al: Lipoprotein (a) levels in patients with myocardial infarction treated with anistreplase: no prediction efficacy but inverse correlation with plasminogen activation in nonpatency. Int J Cardiol 1994;45:109-113.
28. Matsuda S, Arima M, Ohigawa T, Tanimoto K, Takagi A, Kanoh T, et al: Relation between serum lipoprotein (a) residual lesion stenosis of coronary artery after myocardial infarction without reperfusion therapy. Jpn Heart J 2004;45:397-407.
29. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U: Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-592.
30. Dangas G, Mehran R, Harpel C, Sharma SK, Marcovina SM, Dube G, et al: Lipoprotein (a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998;32:2035-2042.
31. Yazici M, Demircan S, Durna K, Sahin M: Lipoprotein (a) levels in patients with unstable angina and their relationship with atherothrombosis and myocardial damage. Int J Clin Pract 2005;59:150-155.
32. Stubbs P, Seed M, Moseley D, O'Connor B, Collinson P, Noble M: A prospective study of the role of lipoprotein (a) in the pathogenesis of unstable angina. Eur Heart J 1997;18:603-607.
33. Zampoulakis JD, Kyriakousi AA, Poralis KA, Karaminas NT, Palermos ID, Chimonas ET, et al: Lipoprotein (a) is related to the extent of lesions in the coronary vasculature and to unstable syndromes. Clin Cardiol 2000;23:895-900.
34. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S: Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003;49:1785-1796.
35. Berk BC, Weintraub WS, Alexander RW: Elevation of C-reactive protein in 'active' coronary artery disease. Am J Cardiol 1990;65:168-172.
36. Heeschen C, Hamm CW, Bruemmer J, Simoons M: Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. J Am Coll Cardiol 2000;35:1535-1542.
37. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-1147.
38. Sabatine MS, Morrow DA, De Lemos JA, Gibson CM, Murphy SA, Rifai N, et al: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponine I, Creactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-1763.
39. Kushner I, Sehgal AR: Is high-sensitivity Creactive protein an effective screening test for cardiovascular risk? Arch Intern Med 2002;162:867-869.
40. Lowe GDO: Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005;3:1618-1627.
41. Bazzino O: Prognostic value of the determination of C-reactive protein in unstable angina. Rev Esp Cardiol 2001;54:1-6.
42. Yip HK, Wu CJ, Hang CL, Chang HW, Yang CH, Hsieh YK, et al: Levels and values of inflammatory markers in patients with angina pectoris. Int Heart J 2005;46:571-581.
43. Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP, Franklin BA, et al: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
44. Brown E, Giles W, Croft J: White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001;54:316-322.
45. Lee CD, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe D: White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and white men and women: atherosclerosis risk in communities study. Am J Epidemiol 2001;154:758-764.